Stock listing

NASDAQ:MBX MBX Biosciences, Inc. Stock

Home listing (NASDAQ) of MBX Biosciences, Inc.

Follow MBX Biosciences, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:MBX

$49.61 USD -1.10 (-2.2%)

Close on Oct 16, 2026

Since Jul 6, 2026 -14.0% · daily closes, Jul 6, 2026 – Oct 16, 2026, adjusted for splits
Day range
$49.23 – $50.83 USDOct 16, 2026
Volume
818,907 sharesOct 16, 2026
Market value
$2.39B USDAt the close on Oct 16, 2026 · price × 48.16M shares outstanding
MBX Biosciences, Inc. logo
Ticker
NASDAQ:MBX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Calls

Replays

  • MBX Biosciences (NASDAQ:MBX) Q3 2025 Earnings Call

    Thu, Aug 14, 2025 · 10:00 AM ET

    Watch Transcript

  • MBX Biosciences (NASDAQ:MBX) Q2 2025 Earnings Call

    Thu, May 15, 2025 · 11:00 AM ET

    Watch Transcript

  • MBX Biosciences (NASDAQ:MBX) Q1 2025 Earnings Call

    Thu, Feb 13, 2025 · 11:00 AM ET

    Watch Transcript

Latest news

MBX Biosciences to Participate in Upcoming November Investor Conferences

Oct 13, 2026

MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer

Sep 8, 2026

MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism

Aug 27, 2026

MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights

Aug 6, 2026

MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth

Jul 13, 2026

MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism

Jun 12, 2026

MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026

Jun 1, 2026

MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City

May 26, 2026

MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing

May 11, 2026

MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award

May 7, 2026

All MBX Biosciences, Inc. news

Decks

MBX Biosciences, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
25 in the last 12 months · 54 in all · newest Oct 13, 2026 · oldest 2024
Calls
3 calls with a replay · 3 with a transcript · latest Aug 14, 2025
Decks
5 decks · latest Aug 6, 2026

Where MBX Biosciences, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:MBX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:MBXBOATSUnited StatesUSD

Log in to ask 6ix AI your own questions about MBX Biosciences, Inc.